Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry
-
Published:2020-06-05
Issue:1
Volume:15
Page:
-
ISSN:1750-1172
-
Container-title:Orphanet Journal of Rare Diseases
-
language:en
-
Short-container-title:Orphanet J Rare Dis
Author:
Sánchez-Martínez Rosario, Iriarte Adriana, Mora-Luján José María, Patier José Luis, López-Wolf Daniel, Ojeda Ana, Torralba Miguel Angel, Juyol María Coloma, Gil Ricardo, Añón Sol, Salazar-Mendiguchía Joel, Riera-Mestre AntoniORCID, Alonso-Cotoner C., Añón S., Beneyto M., Bermejo-Olano M. M., Cerdà P., Cruellas F., De Los Santos A., Díez L., Fernández A., García-Morillo J. S., Gil R., Gómez-Cerezo J. F., Gómez del Olmo V., González-García A., Iriarte A., Iglesias P., Juyol M. C., López-Osle N., López M., López-Wolf D., Mora-Luján J. M., Moreno M., Ojeda A., Patier J. L., Pérez de León J. A., Perez M. L., Riera-Mestre A., Rivera S., Rodríguez S., Sánchez-Martínez R., Torralba M. A., Zarrabeitia R.,
Abstract
Abstract
Background
Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disease with autosomal dominant inheritance. Disease-causing variants in endoglin (ENG) and activin A receptor type II-like 1 (ACVRL1) genes are detected in more than 90% of cases submitted to molecular diagnosis.
Methods
We used data from the RiHHTa (Computerized Registry of Hereditary Hemorrhagic Telangiectasia) registry to describe genetic variants and to assess their genotype-phenotype correlation among HHT patients in Spain.
Results
By May 2019, 215 patients were included in the RiHHTa registry with a mean age of 52.5 ± 16.5 years and 136 (63.3%) were women. Definitive HHT diagnosis defined by the Curaçao criteria were met by 172 (80%) patients. Among 113 patients with genetic test, 77 (68.1%) showed a genetic variant in ACVRL1 and 36 (31.8%) in ENG gene. The identified genetic variants in ACVRL1 and ENG genes and their clinical significance are provided. ACVRL1 mutations were more frequently nonsense (50%) while ENG mutations were more frequently, frameshift (39.1%). ENG patients were significantly younger at diagnosis (36.9 vs 45.7 years) and had pulmonary arteriovenous malformations (AVMs) (71.4% vs 24.4%) and cerebral AVMs (17.6% vs 2%) more often than patients with ACVRL1 variants. Patients with ACVRL1 variants had a higher cardiac index (2.62 vs 3.46), higher levels of hepatic functional blood tests, and anemia (28.5% vs 56.7%) more often than ENG patients.
Conclusions
ACVRL1 variants are more frequent than ENG in Spain. ACVRL1 patients developed symptomatic liver disease and anemia more often than ENG patients. Compared to ACVRL1, those with ENG variants are younger at diagnosis and show pulmonary and cerebral AVMs more frequently.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Reference41 articles.
1. The portal for rare diseases and orphan drugs. Available online: https://www.orpha.net/consor/cgi-bin/index.php. Accessed 23 Nov 2019. 2. Kjeldsen AD, Vase P, Green A. Hereditary hemorrhagic telangiectasia (HHT): a population-based study of prevalence and mortality in Danish HHT patients. J Intern Med. 1999;245:31–9. 3. Donaldson JW, McKeever TM, Hall IP, Hubbard RB, Fogarty AW. The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: a population-based study. Thorax. 2014;69:161–7. 4. Shovlin CL, Buscarini E, Kjeldsen AD, Mager HJ, Sabba C, Droege F, et al. European reference network for rare vascular diseases (VASCERN) outcome measures for hereditary Haemorrhagic telangiectasia (HHT). Orphanet J Rare Dis. 2018;13:136. 5. McDonald J, Wooderchak-Donahue W, VanSant WC, Whitehead K, Stevenson DA, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015;6:1.
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|